Jasper Therapeutics
Redwood City, California, United States · Biotechnology, Health Care, Therapeutics
Our mission is to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, safer and more effective conditioning for monogenetic diseases and new engine
Key facts
- Headquarters
- Redwood City, California, United States
- Employees
- 51
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (JSPR)
- Website
- jaspertherapeutics.com
- Company page
Recent activity at Jasper Therapeutics
- : SEC 8-K (8.01): On October 15, 2026, Jasper Therapeutics, Inc. announced that it completed enrollment of the IgA nephropathy (IgAN) cohort in its Phase 2 basket study for the drug vensobafusp alfa (KP104). This completion marks a significant milestone in their clinical trials, potentially advancing the treatment options available for IgAN. This event aligns with the company's strategic objectives in expanding its research and development pipeline and highlights their continued commitment to addressing unmet medical needs. The press release detailing this announcement is included as Exhibit 99.1.
- : SEC 8-K (8.01): On October 7, 2026, Jasper Therapeutics, Inc. announced the commencement of an offer to holders of its outstanding warrants for common stock issued during an underwritten public offering on September 18, 2025. The company is offering $0.324 in cash per warrant tendered, with 12,345,707 warrants outstanding as of October 6, 2026. Each warrant allows the purchase of one share of common stock at an exercise price of $2.92. The offer is contingent upon the terms outlined in the Offer to Purchase dated October 7, 2026, and will remain open until one minute after 11:59 p.m. on the closing date. This strategic move is aimed at potentially reducing the number of outstanding warrants and strengthening the company's capital structure.
- : Jasper Therapeutics Appoints Interim Executives Following CFO Resignation
- : SEC 8-K (5.02): On September 23, 2026, Herb Cross resigned from his positions as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, and Corporate Secretary of Jasper Therapeutics, Inc. due to other professional pursuits. Following his resignation effective October 9, 2026, the board appointed Jeet Mahal, the President and CEO, as interim Principal Financial Officer, Rick Ruiz as interim Principal Accounting Officer, and Matthew Ros as interim Corporate Secretary, all effective from the resignation date. This leadership change may influence the company's strategic direction and financial oversight during the transition period.
- : SEC 8-K (1.01):
- : Jasper Therapeutics
- : SEC 8-K (8.01):
- : SEC 8-K (5.02): On July 16, 2026, Vishal Kapoor and Scott Brun, M.D., resigned from the Board of Directors, with their resignations effective immediately after the Effective Time as part of a Merger Agreement. The Board subsequently reduced the number of authorized members from eight to six. Concurrently, the Board appointed Patrick Crutcher to the Board as a Class I director, effective immediately after the Effective Time. Mr. Crutcher brings extensive experience from various biotechnology companies and has engaged in multiple significant company acquisitions. He entered into a standard indemnification agreement with the Company upon his appointment.
- : Jasper Therapeutics acquires Kira Pharmaceuticals
- : SEC 8-K (7.01): On July 16, 2026, Jasper Therapeutics, Inc. announced the completion of its acquisition of Kira Pharmaceuticals, which was involved in developing complement therapies for immune-mediated diseases, in an all-stock transaction. The transaction is part of a broader strategic move to enhance their product portfolio in immunology. Additionally, Jasper Therapeutics entered into a securities purchase agreement for a private placement financing, raising gross proceeds of $132 million to support this acquisition and related operations. This significant financial maneuver shows Jasper's commitment to expanding its market presence and capabilities in treating complex diseases.
Jasper Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Venture | $132.0M |
Leadership
- Ronald, CEO & President
- Mark, Vice President of IT and Facilities at Jasper Therapeutics
- Rick Ruiz, Vice President
- Jeet Mahal, President
- Herb Cross, Chief Financial Officer
Verified email and direct lines for Jasper Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Jasper Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Jasper Therapeutics in the news
- Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire (Aug 14, 2026)
- Patients with chronic spontaneous urticaria see well-controlled disease with briquilimab - Healio (Jan 14, 2025)
- Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire (Sep 09, 2026)
- Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation - Business Wire (May 06, 2021)
- Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants - GlobeNewswire (Oct 07, 2026)
- Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value - GlobeNewswire (Jun 01, 2026)
- Jasper Therapeutics Announces Merger with Kira Pharmaceuticals - GlobeNewswire (Jul 16, 2026)
- Jasper Therapeutics Announces Completion of Enrollment in - GlobeNewswire (Oct 15, 2026)
Companies similar to Jasper Therapeutics
- MeiraGTx Holdings plc · Biotechnology, Health Care, Therapeutics
- Omnio · Biotechnology, Health Care, Therapeutics
- BioAtla · Biotechnology, Health Care, Therapeutics
- Redx Pharma · Biotechnology, Health Care, Therapeutics
- Transgene · Biotechnology, Health Care, Therapeutics
About Jasper Therapeutics: questions and answers
What does Jasper Therapeutics do?
Our mission is to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, safer and more effective conditioning for monogenetic diseases and new engine
Where is Jasper Therapeutics headquartered?
Jasper Therapeutics is headquartered in Redwood City, California, United States.
How many employees does Jasper Therapeutics have?
Jasper Therapeutics has about 51 employees.
Has Jasper Therapeutics raised funding?
Yes. Fundz has recorded 1 funding event for Jasper Therapeutics. The most recent, $132.0M, was in Aug 2026.
Who leads Jasper Therapeutics?
Ronald is a CEO & President at Jasper Therapeutics.
What is the latest news on Jasper Therapeutics?
On Oct 15, 2026, SEC 8-K (8.01): On October 15, 2026, Jasper Therapeutics, Inc. announced that it completed enrollment of the IgA nephropathy (IgAN) cohort in its Phase 2 basket study for the drug vensobafusp alfa (KP104). This completion marks a significant milestone in their clinical trials, potentially advancing
Is Jasper Therapeutics a public company?
Yes. Jasper Therapeutics is publicly traded under the ticker JSPR.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy